Sugi Predict

Sugi Predict / Compounds / SCHEMBL29391423

SCHEMBL29391423

SCHEMBL29391423

COc1cccc(-c2ccc([C@@H](Oc3cc(-c4ccc(C[C@H](N)C(=O)O)cc4)nc(N)n3)C(F)(F)F)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPH1 P17752 20/20 1.00
▸ TPH2 Q8IWU9 11/20 1.00
▸ ADORA3 P0DMS8 2/20 0.55
▸ SLC6A2 P23975 2/20 0.55
▸ AGTR1 P30556 2/20 0.55
▸ SLC6A4 P31645 2/20 0.55
▸ CCKAR P32238 2/20 0.55
▸ SLC6A3 Q01959 2/20 0.55
▸ F2 P00734 1/20 0.55
▸ ESR1 P03372 1/20 0.55
▸ DRD1 P21728 1/20 0.55
▸ PTGS1 P23219 1/20 0.55
▸ PTGS2 P35354 1/20 0.55
▸ DRD3 P35462 1/20 0.55
▸ MLNR O43193 1/20 0.47
▸ NR3C1 P04150 1/20 0.47
▸ ADRA2B P18089 1/20 0.47
▸ ADRA2C P18825 1/20 0.47
▸ MC3R P41968 1/20 0.47
▸ HTR3A P46098 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL308718 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL2364480 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL308719 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL13878219 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL870345 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL870344 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
Fumaric Acid SCHEMBL2927924 0.96 TPH1 (0.93) TPH1TPH2ADORA3SLC6A2AGTR1
Maleic Acid SCHEMBL2720175 0.96 TPH1 (0.93) TPH1TPH2ADORA3SLC6A2AGTR1
Fumaric Acid SCHEMBL2927928 0.96 TPH1 (0.93) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL12128916 0.94 TPH1 (0.89) TPH1TPH2ADORA3SLC6A2AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4659023-A1 METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY Immusmol SAS (FR) 2025-12-10 — — EP claimed
WO-2024161038-A1 METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY IMMUSMOL SAS (FR) 2024-08-08 — — WO claimed
US-20220146492-A1 CELL MEMBRANE PERMEABILITY RESTORING THERAPY SHINE IAN BASIL (US) 2022-05-12 — — US claimed
EP-3953000-A1 CELL MEMBRANE PERMEABILITY RESTORING THERAPY Shine, Ian Basil (US) 2022-02-16 — — EP claimed
EP-4739314-A1 USE OF TRYPTOPHAN HYDROXYLASE 1 (TPH1) INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS Institut National de la Santé et de la Recherche Médicale (FR) 2026-05-13 — — EP disclosed
EP-4659023-A1 METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY Immusmol SAS (FR) 2025-12-10 — — EP disclosed
US-12454520-B2 Protein degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-10-28 — — US disclosed
US-20250214969-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 — — US disclosed
CN-120157564-A Fluorine atom substituted alpha-deuterated chiral alcohol compound and enzyme catalysis preparation method and application thereof 天津大学 2025-06-17 — — CN disclosed
WO-2025092103-A1 IMAGE ENCODING METHOD, IMAGE DECODING METHOD, AND RELATED APPARATUS 华为技术有限公司 2025-05-08 — — WO disclosed
CN-119919329-A Image coding method, image decoding method and related device 华为技术有限公司 2025-05-02 — — CN disclosed
US-20250034189-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2025-01-30 — — US disclosed
US-20220326486-A1 Lens Assembly SINTAI OPTICAL (SHENZHEN) CO., LTD. (CN) 2022-10-13 — — US disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 — — US disclosed
US-20220244263-A1 METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-08-04 — — US disclosed
CN-113462602-B Corksaiella radicata ZJPH202011 and application thereof 浙江工业大学 2022-05-24 — — CN disclosed
US-20220146492-A1 CELL MEMBRANE PERMEABILITY RESTORING THERAPY SHINE IAN BASIL (US) 2022-05-12 — — US disclosed
US-11278549-B2 Method of treating obesity MCMASTER UNIVERSITY (CA) 2022-03-22 — — US disclosed
US-20220073516-A1 CRYSTALLINE SPIROCYCLIC COMPOUND, A DOSAGE FORM CONTAINING, A METHOD FOR USING IN TREATMENT OF DISEASE, AND A METHOD FOR RECRYSTALLIZING ALTAVANT SCIENCES GMBH (CH) 2022-03-10 — — US disclosed
EP-3953000-A1 CELL MEMBRANE PERMEABILITY RESTORING THERAPY Shine, Ian Basil (US) 2022-02-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11278549-B2 Method of treating obesity GPR119, HTR2A, GIPR TPH1 43/4885TPH2 25/4885ADORA3 107/4885
US-12454520-B2 Protein degraders and uses thereof MDM2, CUL1, PSMG3 TPH1 1601/4885TPH2 1930/4885ADORA3 4716/4885
US-20220073516-A1 CRYSTALLINE SPIROCYCLIC COMPOUND, A DOSAGE FORM CONTAINING, A METHOD FOR USING IN TREATMENT OF DISEASE, AND A METHOD FOR RECRYSTALLIZING PKD2, PKD1, REN TPH1 2527/4885TPH2 2817/4885ADORA3 3743/4885
US-20250214969-A1 PROTEIN DEGRADERS AND USES THEREOF MDM2, CUL1, PSMG3 TPH1 1601/4885TPH2 1930/4885ADORA3 4716/4885
US-20250034189-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD1, OCIAD2, LEF1 TPH1 4494/4885TPH2 4582/4885ADORA3 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.